Register Login

ONKURE THERAPEUTICS, INC. (OKUR)

SymbolOKUR
NameONKURE THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address18575 JAMBOREE ROAD,SUITE 275-S, IRVINE, California, 92612, United States
Telephone+1 619 733-3852
Fax—
Email—
Websitehttps://www.onkuretherapeutics.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001637715
Description

OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3K and has multiple programs designed to enable targeting of this key oncogene.

Additional info from NASDAQ:
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3K and has multiple programs designed to enable targeting of this key oncogene.

2026-08-14 18:02

New Form SCHEDULE 13G/A - OnKure Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097335 <b>Size:</b> 13 KB

Read more
2026-08-14 17:23

New Form SCHEDULE 13G/A - OnKure Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000921895-26-002177 <b>Size:</b> 25 KB

Read more
2026-08-14 17:21

New Form SCHEDULE 13G/A - OnKure Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001493152-26-038382 <b>Size:</b> 11 KB

Read more
2026-08-11 20:43

Mathers Edward T 🟢 acquired 22.4K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.14 Transaction Date: Aug 07, 2026 | Filing ID: 344874

Read more
2026-08-11 20:40

Ratcliffe Liam 🟢 acquired 22.4K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.14 Transaction Date: Aug 07, 2026 | Filing ID: 000005

Read more
2026-08-11 20:39

Phillips Andrew John 🟢 acquired 22.4K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.14 Transaction Date: Aug 07, 2026 | Filing ID: 000003

Read more
2026-08-11 20:39

Manke Isaac 🟡 adjusted position in 300.0K shares (3 derivative) of OnKure Therapeutics, Inc. (OKUR) at $18.20 ($1.6M) Transaction Date: Aug 07, 2026 | Filing ID: 000002

Read more
2026-08-11 20:37

Jansen Valerie Malyvanh 🟢 acquired 22.4K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.14 Transaction Date: Aug 07, 2026 | Filing ID: 000002

Read more
2026-08-11 20:36

GREY MICHAEL G 🟢 acquired 22.4K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.14 Transaction Date: Aug 07, 2026 | Filing ID: 000006

Read more
2026-08-11 20:31

Carruthers R Michael 🟢 acquired 22.4K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.14 Transaction Date: Aug 07, 2026 | Filing ID: 000002

Read more